9JUN

Thinnest US health bench faces PHEIC

3 min read

09:58UTC

Jay Bhattacharya holds NIH Director and acting CDC Director simultaneously; Brian Christine, an Alabama urologist, is the Senate-confirmed HHS Assistant Secretary for Health since October 2025.

← Back to Ebola outbreak gets an R0, and a fork Jump to analysis ↓

ScienceDeveloping

Key takeaway

Three of the federal positions that ran 2018 Equateur have no permanent occupant today.

Brian Christine, an Alabama urologist Senate-confirmed in October 2025, holds the Assistant Secretary for Health post at the US Department of Health and Human Services, the second-ranking health official below the Secretary ¹. Jay Bhattacharya, confirmed as NIH Director in March 2025, has held the acting CDC Director role concurrently since shortly after confirmation. Bhattacharya posted on X in January 2024 that "the best pandemic preparedness playbook for the United States is making America healthy again" ²; the post remains the publicly stated approach.

When the CDC ran the 2018 Equateur response under Robert Redfield, the agency had a confirmed director, a confirmed FDA commissioner and a confirmed Office of the Assistant Secretary for Preparedness and Response head simultaneously. None of those three positions currently has a permanent occupant. An Assistant Secretary for Health from urology, paired with a single individual holding NIH and acting CDC, gives the federal public-health roster its thinnest senior bench of the post-2014 era at the first Bundibugyo PHEIC in history. The concurrent H5N1 pressure across Idaho dairy operations and Bangladesh surveillance sits on the same bench at the same time.

Deep Analysis

In plain English

In a health emergency, the United States has several key agencies: the Centers for Disease Control (CDC), the Food and Drug Administration (FDA), and the Office of the Assistant Secretary for Preparedness and Response (ASPR). Each normally has a Senate-confirmed director who can make major decisions and speak with authority. As of May 2026, none of those three positions has a confirmed permanent occupant. Jay Bhattacharya, the NIH Director, is also filling in as acting CDC head. The second-ranking health official, Brian Christine, is a urologist with no prior public health emergency role. That is the team managing the first Bundibugyo Ebola emergency in history, while also dealing with a bird flu surge in Idaho dairy farms {{EVREF:/t/pandemics-and-biosecurity/2/idaho-dairy-h5n1-1-to-59-herds-in-twelve-days/}}.

What could happen next?

Risk
Multi-threat concurrent pressure across the Bundibugyo PHEIC, Idaho H5N1, and Andes hantavirus, with no confirmed leadership at CDC, FDA, or ASPR, creates conditions where interagency resource allocation decisions may be delayed or uncoordinated.
Consequence
CDC's absence from the WHO AFRO release while present in the Africa CDC statement may reflect the acting leadership's difficulty committing field resources without confirmed authority to approve budgetary deployment.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: During the 2018 Equateur Ebola outbreak, confirmed senior US public health roles were held by Robert Redfield (CDC Director, confirmed March 2018), Scott Gottlieb (FDA Commissioner, confirmed May 2017), and Robert Kadlec (ASPR, confirmed August 2017). Three confirmed senior officials at CDC, FDA, and ASPR simultaneously provided clear interagency authority lines for the response. That outbreak was contained in three months.

Counter-parallel: During the early COVID-19 response in January-March 2020, Robert Redfield was confirmed as CDC Director and Alex Azar as HHS Secretary, giving the US a fully staffed leadership bench.

The US still missed its 14 January 2020 WHO early warning, failed to scale domestic testing until late March, and did not implement coordinated PPE logistics until mid-April. Confirmed leadership is a structural prerequisite for clear decision authority; it does not guarantee effective response execution.

Consensus view: Former HHS Assistant Secretary for Preparedness and Response Robert Kadlec, WHO held confirmed roles at ASPR under three administrations, observed in public commentary that the simultaneous absence of confirmed CDC Director, FDA Commissioner, and ASPR head means outbreak-response decisions must be escalated to the HHS Secretary level for any cross-agency coordination, adding decision latency at the moment outbreak response most requires speed.

Counter-view: Former FDA Commissioner Scott Gottlieb (AEI health policy fellow) wrote in the Wall Street Journal in April 2026 that acting and interim officials can be operationally effective when career staff infrastructure remains intact, and argued that the CDC's career epidemiology and emergency response staff at the agency level have more institutional capacity than any single confirmed director.

Gottlieb's position is that personnel gaps at Senate-confirmed level matter less than programmatic budget and workforce continuity.

Key tension: Whether the acting-official structure creates real decision-latency in a multi-threat environment (Bundibugyo PHEIC + Idaho H5N1 + Andes hantavirus) or whether Gottlieb's career-staff argument holds when all three threats compete for the same budget and interagency attention simultaneously.

Sources:Wikipedia / Senate records / CNN Politics·Wikipedia / Senate records / CNN Politics·Science-Based Medicine (citing Bhattacharya's X post)

Mentions:Jay Bhattacharya →Brian Christine →NIH →United States →Bangladesh →H5N1 →Idaho →Wall Street Journal →PHEIC →Alabama →World Health Organization →Bundibugyo ebolavirus →HHS →CDC →

First Reported In

Update #3 · WHO calls Ebola PHEIC, no treatment exists

Wikipedia / Senate records / CNN Politics· 17 May 2026

Read original →

Causes and effects

This Event

Thinnest US health bench faces PHEIC

Three of the federal positions that ran 2018 Equateur, the CDC Director, the FDA Commissioner and the ASPR head, have no permanent occupant at the first Bundibugyo PHEIC.

Led to

Kenyan court halts US quarantine site

The dual NIH/acting-CDC role (ID:3364) is part of the thin US public-health bench context for the unilateral quarantine and screening decisions.

Occurred 29 May 2026

Read story →

Different Perspectives

World Health Organization

WHO's DON606 recalibration to confirmed-only reporting gives the clean baseline the CDC model rests on, but the apparent fall from 1,040 to 534 carries misinterpretation risk WHO communications have not pre-empted. The PABS deadlock ahead of IGWG7 and continuing MBP134/remdesivir assessment without authorisation make WHO the body most able to accelerate the two decisions that could change the outbreak's trajectory.

European Union (ECDC)

ECDC's Week 23 CDTR tracked four simultaneous non-Ebola signals: the Dermatophilus congolensis novel-transmission cluster across France, Germany and Spain; a 4.2-fold malaria surge in Mayotte; the Salmonella ST2045 multi-country cluster; and two new Saudi MERS cases. The continental early-warning layer is carrying a full multi-pathogen picture while Bundibugyo dominates headlines.

Uganda

Uganda's 19 confirmed cases are concentrated in Kampala and Wakiso, an urban cluster that applied the 2022 Sudan-ebolavirus playbook; the Bwera border laboratory shortens cross-border confirmation to same-day. Uganda's regulatory authority must co-sign before MBP134 or remdesivir can dose any patient.

Democratic Republic of the Congo

Kinshasa shares Bundibugyo sequence data in real time with no treaty-guaranteed access to the vaccines that data informs, and its health minister called the US entry ban discriminatory while negotiating an early lift. DRC accounts for 515 of 534 confirmed cases and faces IS-controlled access blockades in Mambasa that health authorities cannot resolve.

United States (HHS/CDC)

HHS expanded the Ebola entry ban to green-card holders on 5 June, widening a restriction expiring around 17 June against WHO advice. The CDC simultaneously published the R0=2.51 modelling, the sharpest analytical contribution to the response, from a federal bench that holds the NIH and acting CDC director roles in one person.

Imperial College London / Cori and Ferguson

Anne Cori and Neil Ferguson place the case-fatality ratio at 30 to 40 per cent and read the 6.8-to-1 suspected-to-confirmed ratio as evidence that the laboratory figure understates true lethality. Many people die before a swab reaches them.